Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6Thoracic 2Lymphoid 2Gastrointestinal 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Carcinoid Tumor 2Sarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1

Interventions

Fluorodeoxyglucose F18 3Doxorubicin 3Cyclophosphamide 3surufatinib 2fludarabine 2entrectinib 2Radiotherapy 2Nivolumab 2Ifosfamide 2Filgrastim 2Drug Therapy 2Cisplatin 2tivozanib 1tislelizumab 1tipifarnib 1selpercatinib 1romidepsin 1repotrectinib 1regorafenib 1pembrolizumab 1milademetan 1ganitumab 1fludarabine phosphate 1entinostat 1dostarlimab 1conatumumab 1cixutumumab 1cabozantinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × ganitumab × Endocrine × Clear all
NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡